Skip to main content

Navigating the Complexity of Psychedelics' Therapeutic Potential in Minors

Edited by:

Philippe Auby, MD, Cognition Behaviour Technology (CoBTeK), Université Côte d'Azur, France
Joerg Michael Fegert, MD, University Hospital Ulm, Germany

Benedetto Vitiello, MD, University of Turin, Italy
Jacinta Tan, MD, PhD, My Lighthouse Ltd, United Kingdom
Kim Kuypers, PhD, Maastricht University, The Netherlands
Iliyan Ivanov, MD, Mount Sinai Hospital, New York, United States of America
Amanda Downey, MD, University of California, San Francisco, United States of America

Submission Status: Open   |   Submission Deadline: 10 February 2025

Child and Adolescent Psychiatry and Mental Health is calling for submissions to our Collection on the complexity of psychedelics' therapeutic potential in minors.

Image credit: © Zim /

About the Collection

Child and Adolescent Psychiatry and Mental Health is calling for submissions to our Collection on Navigating the Complexity of Psychedelics' Therapeutic Potential in Minors.

After having been banned for reasons that had little to do with science, psychedelics resurfaced and now spark hopes and enthusiasm, with hundreds of clinical trials registered on and the first psychedelic-assisted therapy submitted for approval to the FDA in late 2023 for PTSD. Therefore, it is crucial to explore this research domain thoroughly and cautiously to avoid unrealistic enthusiasm and politicization of science, as seen in the 1960s.

Psychedelics and compounds that affect consciousness should undergo the same rigorous development process as any other drug, including their potential use in pediatric psychopharmacology. Simply refusing access to psychedelics to adolescents solely based on their age will not stand if, for instance, the use of psychedelics dramatically changes the course of Anorexia Nervosa in young adults.

This series wants to pave the way to these uncharted psychedelic pediatric territories. We aim to offer a unique forum to discuss topics ranging from investigating the neurodevelopmental and neurobiological effects of psychedelics in a developing brain, emphasizing ethical considerations, highlighting assessments of risks versus benefits, promoting best practices for clinical trials, reflecting on the regulatory moving framework to exploring the potential integration of psychedelics in pediatric therapeutic strategies.

Interested authors are welcome to contact the guest editor, Dr. Philippe Auby, at to propose a manuscript and receive some initial input on suitability for this special collection.

  1. Ketamine and its enantiomer have rapid and robust effects on depressive symptom and suicidal ideation. Little is known about their cognitive effects in adolescents. We aimed to evaluate the short-term effect o...

    Authors: Xiaofeng Lan, Chengyu Wang, Fan Zhang, Haiyan Liu, Weicheng Li, Yanxiang Ye, Zhibo Hu, Siming Mai, Yuping Ning and Yanling Zhou
    Citation: Child and Adolescent Psychiatry and Mental Health 2023 17:108

Submission Guidelines

Back to top

This Collection welcomes submission of Research articles and Reviews. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. 

Articles for this Collection should be submitted via our submission system, Snapp. Please, select the appropriate Collection title “Navigating the Complexity of Psychedelics' Therapeutic Potential in Minors" under the “Details” tab during the submission stage.

Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.